Bio-Techne Corp (TECH)

Bio-Techne Corp is a healthcare company listed on NASDAQ as common stock under the ticker TECH. Through its subsidiaries, the company develops, manufactures, and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing customers worldwide. Its operations are organized into two segments: Protein Sciences and Diagnostics and Spatial Biology. The Protein Sciences segment focuses on biological reagents and related tools used in life science research, diagnostics, and cell and gene therapy, including cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. It also provides protein analysis instruments and immunoassays used in automated western blot and multiplexed ELISA workflows. The Diagnostics and Genomics segment develops diagnostic products such as controls, calibrators, assays, exosome-based molecular diagnostics, tissue-based in-situ hybridization assays, and genetic and oncology kits. The company, formerly known as Techne Corporation, adopted the Bio-Techne name in 2014 and is headquartered in Minneapolis, Minnesota.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-TECH
$67.47
-5.7% Downside
Fair
$70
-2.2% Downside
Fair
Good
0.32
0.4%
August 11, 2026
101.9x
5.4x
9.2x
11.164 B
10.988 B
2.5%
99.6%
18.0
45.5%
246.2%
Valuation • Fair Value

Bio-Techne Corp (NASDAQ-TECH) Fair Value by Valuation Model

Compare the primary fair value estimate for Bio-Techne Corp (NASDAQ-TECH) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$67.47

Estimated downside of 5.7% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$68.96

Discounted cash flow valuation reference.

Ben Graham Formula Value

$7.80

Classic Ben Graham valuation formula reference.

DDM Fair Value

$52.53

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$68.48

Comparable-company valuation reference.

Analyst Price Target

$70

Analysts imply downside of 2.2%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Bio-Techne Corp (NASDAQ-TECH) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Bio-Techne Corp (NASDAQ-TECH)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

1.211 B

Current operating scale indicator.

Revenue Forecast

1.208 B

Forward revenue estimate.

EBITDA

366 M

Current operating profitability reference.

EBITDA Forecast

428.3 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Bio-Techne Corp (NASDAQ-TECH) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Bio-Techne Corp (NASDAQ-TECH)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-2.82

No elevated caution signal from this screen.

Altman Z-Score

18.0

Relatively strong balance-sheet zone.

FCF / Net Income

246.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Bio-Techne Corp (NASDAQ-TECH). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Bio-Techne Corp (NASDAQ-TECH)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 11, 2026

Days to Earnings

21

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.4%

Income yield reference.

Upcoming Dividend

0.32

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

45.5%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Bio-Techne Corp (NASDAQ-TECH), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Bio-Techne Corp (NASDAQ-TECH) Stock Forecast & Technical Outlook

Review Bio-Techne Corp (NASDAQ-TECH) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Bio-Techne Corp (NASDAQ-TECH) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Bio-Techne Corp (NASDAQ-TECH) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Bio-Techne Corp (NASDAQ-TECH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Bio-Techne Corp (NASDAQ-TECH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Bio-Techne Corp (NASDAQ-TECH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Bio-Techne Corp (NASDAQ-TECH)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Bio-Techne Corp (NASDAQ-TECH) has a Hold consensus, with 2 buy, 13 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 13
Sell 0
FAQ Fast Investor Answers

Bio-Techne Corp (NASDAQ-TECH) Stock FAQ

Quick answers about Bio-Techne Corp (NASDAQ-TECH) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$67.47
Estimated downside 5.7%
Valuation Rating
Overvalued
Estimated downside of 5.7%
Analyst Target
$70
Implied downside 2.2%
Financial Health
Good
Current financial-health read

The current fair value estimate for Bio-Techne Corp (NASDAQ-TECH) is $67.47. This implies an estimated downside of 5.7% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 5.7% versus the current market price.

The available analyst price target for Bio-Techne Corp (NASDAQ-TECH) is $70. The analyst target implies estimated downside of 2.2%.

The current financial health read for Bio-Techne Corp (NASDAQ-TECH) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Bio-Techne Corp (NASDAQ-TECH) is August 11, 2026.

Based on the current data, dividend yield is 0.4%, upcoming dividend amount is 0.32.

The current P/E ratio listed for Bio-Techne Corp (NASDAQ-TECH) is 101.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Bio-Techne Corp is 11.164 B.

The current enterprise value listed for Bio-Techne Corp is 10.988 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Bio-Techne Corp is NASDAQ-TECH, and the stock is listed on NASDAQ.

Bio-Techne Corp (NASDAQ-TECH) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Bio-Techne Corp is 2.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Bio-Techne Corp is 99.6%. Free float helps investors understand how much of the share base is available for public trading.